Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Cancer Discov. 2014 Mar 27;4(6):662–673. doi: 10.1158/2159-8290.CD-13-0846

Figure 6. Ceritinib resistant tumors acquired mutations at positions G1202 or F1174.

Figure 6

A) ALK mutational status in ceritinib resistant patient tumors before and after ceritinib treatment. B) Thoracic computed tomography (CT) images of patient MGH011 during crizotinib or ceritinib treatments. Sites of biopsies (red arrows) revealed the presence of different ALK secondary mutations throughout the treatments. Tumor growth observed during ceritinib treatment is consistent with disease progression.